Skip to main content

Mizuho Downgrades FibroGen to Neutral on 'Higher Risk And Uncertainty'

Mizuho analyst Difei Yang downgraded FibroGen to Neutral from Buy with a price target of $29, down from $72.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.